Showing results (21-30 of 453) with videos related to
Sort By:
Pageof 46
Clinical and Molecular Hepatology|November 11, 2024
Hepatitis E as a trigger for acute-on-chronic liver failureMaria Buti, Juan Carlos Ruiz-Cobo, Rafael Esteban, et al.Seminars in Liver Disease|December 6, 2019
Role of Biomarkers in Guiding Cure of Viral Hepatitis BMaria Buti, Mar Riveiro-Barciela, Francisco Rodríguez-Frías, et al.Liver International : Official Journal of the International Association for the Study of the Liver|November 2, 2023
Impact of hepatitis D reflex testing on the future disease burden: A modelling analysisMaria Buti, Raquel Domínguez-Hernández, Adriana Palom, et al.Infection and Drug Resistance|June 23, 2011
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agentsJosep Quer, Maria Buti, Maria Cubero, et al.Journal of Hepatology|October 20, 2009
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximabMayra J Sanchez, Maria Buti, Maria Homs, et al.Hepatology (Baltimore, Md.)|March 27, 2002
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirinMaria Buti, Francisco Sanchez-Avila, Yoav Lurie, et al.Journal of Clinical Microbiology|December 5, 2008
Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapyRosendo Jardi, Francisco Rodriguez-Frias, David Tabernero, et al.European Journal of Gastroenterology & Hepatology|March 13, 2008
Estimating the future health burden of chronic hepatitis B and the impact of therapy in SpainBerlian I Idris, Max Brosa, Jan H Richardus, et al.Hepatology (Baltimore, Md.)|July 9, 2004
Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNARosendo Jardi, Francisco Rodriguez-Frias, Maria Buti, et al.Journal of Hepatology|May 5, 2004
Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirinMaria Buti, Claudia Mendez, Melanie Schaper, et al.Pageof 46